Member Info for sadoldgit

Good afternoon Mafuta. Interesting points have been raised
Sareum as we know has
SDC1801 and SDC1803. Both look very favourable to say the least.
We also have a 27% interest in SRA737 ( of which we eagerly await news of further development)
Shelved at the moment is also Aurora +FLT3

How does Sareum individually price these potential block busters?

As sure as god made little apples there will be interested parties in 1801 and 1802. Tim stated there were parties interested in either 1801 and 1802 but not the both of them. The reason he gave was one would be of interest to oncology and the other immunotherapy and difficult to find a buyer for both. I would be of the opinion that the intersted companies at this time are not mammoth ie do not have billions of pounds of market cap.

At the moment we have 1801 coming up for entry onto Agile platform. Although no 100% guaranteed this should if all goes well lead to the trials being paid for by the platform. (the government are getting desperate and will throw any money they can to find a counter against the devastating financial impact of the Chinese Flu. ( As will be most non 3rd world governments)

How much is 1801 worth as a suitable treatment for Covid 19? Covid is not going anywhere soon. I would expect probably another 5 years at least, to be under a control with the world is back on a stable foothold ie little or no restrictions. The cost to the economy is phenomenal. In the US alone figures are costing 90% of GDP ie 90% of 13 trillion dollars. Dont get me wrong here. I am not suggesting that 1801 is or will be the only suitable treatment to become available.

1801 also has vast potential in many other applications, take sepsis for one example. How much is an effective treatment for that going to be valued at?

1802. again little to no tox indicative of an effective treatment for many forms of cancer. How much is this worth or more importantly, how much revenue can a pharma generate form this before a patent expires?

Aurora plus FLT3, Has very favourable ADME and low toxicity. Been shelved due to concentration of funds on developing Tyk2 and Jak1 inhibitor. How much is this worth? It was only the solubility issues ( I believe the formulation of crystalline compounds for which there will be a patent will go along way to resolving this issue).

For a company to take over the complete caboodle will run into the billions. As the hurdles and key milestones are met then so goes up the price, as consequently the risk factor is reduced.

Citizen79 posted with regards to CHK1. CHk1 i see as of no advantage on its own. Why you may ask. CHK1 blocks P53 from memory which prevents cell reproduction. In effect does not kill a cell. What it does do is in cell mitosis (the dividing of a cell) is stop cell reproduction. Hence when used in combo with a cancer killing agent, the subsequent stress replication blocking of the P53 stops cancer reproduction. Cancer cells do not have a p

A first class post there Stoney40. You have summed up the situation in a nutshell.
Given the origin of the virus vaccines will never resolve the problem on its own. The virus mutates and will continue mutating for years to come.
At the very latest will we know by end of July with regards to 1801 and the Agile platform.
Apart from news in the next week or so with regards to confirmation that current investigations being completed we only then have to await the interpretation of the results. It will be effective but will then find out just how effective it will be.

We have a Tyk 2 and small amount of Jak1 in our compound which indicates favourable selectivity with regards to the treatment of Covid 19, That is of paramount importance. It does not have the serious side effects of NDA issued black box warnings that Jak 2 and Jak 3 inhibitors have. Current treatments are given for EUA by the US government until something better comes along. Kinase inhibitors take a long time to research and to have an acceptable safety profile before they can be accepted into clinical trials. In clinical trials we then need to ascertain that the treatment is significantly more effective than the present form of treatment being used.

Market cap and hence SP will be volatile which can catch the newbie out.

Regards

If and when we get the go ahead for Agile I am not forecasting 100% rises. Around 10 to 15 p per share is my guestimate. Later news with regards to licensing or manufacturing will indeed increase the price and this will be most likely when multiples of the current SP will come to fruition.

This does not however include further progress on either 1802 or Sar737.

These are my views on this and not to be taken as factual.

Red Jed thanks!

Correct me if l am wrong but was there not a series years ago. The Mind of Mr J G Reader? Brilliant programmes but not many made.

Tony Sinclair was a goody ., Johnny Quango another. Adrian Street a goody. Not that l paid much attention. Grandmother used to watch every Saturday. 10 to 5 there she was glue to the box. A 14 inch black and white tv. Had the rabbit ears aerial . Remember knocking that over a couple of times. Wrestling match look liked it was carried out in a snow storm for a while until aerial sited correctly.
Ah the good old days as a child.

A good age 80. Yes long blonde curly hair. All the old age ring side battle axes used to wallop him with their handbag or the occasional beating with or a poke in the ar5e with a brolley.
Pat Roach of Aufedersehen Pet was around too.
Regards

You're going back to the 70's there Krusty. You missed old Jacky Pollo too. Not sure if spelled correctly

Good morning citizen79. A great post from you as usual. Jak1 can prove problematic as we know. However as far as l know our SDC1801 is Tyk 2 and Jak1. There exists only a small amount of Jak1 in our inhibitor which Tim believed to be the optimum amount. In theory Jak 1 is great at pressing the right keys but unfortunately presses some wrong ones too. Not as serious as Janus kinase 2 and 3 however
I would postulate that due to the no to very low toxicity levels at present claimed for our 1801 that that no problems with side effects should be encountered.
I am of the opinion that Tk2 2 units own maybe slightly lacking due to the non selection of an interferon pathway.

Will post more on the subject when l can locate the latest updated research material again with regards to Covid 19.
Regards

Thanks Stoney. I will add that some of the immunomodulators have some particularly nasty adverse effects. Again this must be down to selectivity.
With regards to pathways it does get very complex. Tim and co have had plenty of time to work on this. I am certain with their expertise and attention to detail it will come out trumps.
Regards

IL-6 and IL-6R can be inhibited by Jak1 and Tyk2.

A good link to the Janus kinases I have attached below. Tyk 2 and an optimal amount of Jak1 looks to be spot on.

https://www.rndsystems.com/pathways/jak-stat-signaling-pathway#:~:text=The%20Jak%2FSTAT%20pathway%20is%20a%20putative%20intracellular%20signaling,thus%20utilize%20intracellular%20enzymes%20to%20initiate%20downstream%20signaling.

According to a source reporting early-stage clinical trials on potential COVID-19 post-infection therapies, there were over 230 Phase II trials underway or planned to start by October 2020.[2]

As the spike protein changes with Covid 19 it will require constant vaccine update to be effective, will always be a game of playing catch up. 7 billion people in the world. As soon as a newer more virulent strain appears the vaccine will become less effective. There are reports that the Covid 19 originated by shearing the bat coronavirus and HIV. The Bat corona virus is 99% of Covid 19. This has not been reliably confirmed as yet, but perhaps the way in which the Covid 19 mutates and produces newer strains in HIV infected patients warrants serious investigation.

Regards all and goodnight

Look up on the characteristics of immunomodulation. Interesting read

https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/

I have just found this and will peruse when time permits.

https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/

That speaks volumes Unite. The BOD know how much the market cap is worth in the longer term. They know more than we do. They are in communications with interested parties. Just a matter of crossing the T's and dotting the I's I would guess.

All looks good and at the end of the day we are above 7p

Regards

SD I posted intentionally to remove the constant subject of Senators Viewpoint. In doing so removing the infelicitous, self important, named pedestal, viewpoint subject topic.

Regards

'I'm off for a round of golf now with some market contacts and those in the know.'

Joined April the 9th 2021 .

Says it all really and very self incriminating.

I will have a look Mafuta. Need to identify molecule and look it up from there. It is me thinks people jumping on the bandwagon as government are desperate to end this financial quagmire. They have to be seen to be doing something. But I do see Sareum streets ahead at the moment. TYK2 has been thoroughly tested in preclinical and looks to me to be in a class of its own with regards to a cytokine reduction and as a probable treatment on its own or in combination.

Regards

No problems SD. Apology accepted. will have a scan through posts to see.

I will look through his posting history and look at it from there.

Regards

Not really aware of his post golfing comment or whatever, As for collusion ?

Posted 11.14
Senekotbumspeaker. In what capacity are you to warn people what you think will happen on this site. Your only intention is to try and drive the price down in a grubby little attempt to buy in lower.

Posted 13.30
Senator only been here since April 21. 'Trusted and respected investors like himself.' A fake is all he is. No credibility at all. You have to laugh.

Had no access to site since around 13.40. away from due to nature of work So know of no golfing whatever.

Draw your own conclusion from my reply, look forward to your response.

I cannot be arsed anymore in these petty little squabbles. The board gets diverted away from its real intent.
Regards